You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Unlike the Hi-C chromosome conformation assay, the Pore-C technique reveals information that's lost with short-read sequencing.
Veracyte has also acquired Nanostring's Prosigna breast cancer and LymphMark lymphoma assays and plans to develop diagnostic tests using the nCounter platform.
The deals with Covance, NeoGenomics Laboratories, and Navigate BioPharma Services aim to expand access to NanoString's PanCancer IO 360 Gene Expression Panel.
The study supports the use of Envisia to help with the diagnosis of idiopathic pulmonary fibrosis, particularly in patients without a clear radiological result.
The company, which previously focused on the development of multiplex PCR assays, is hoping to make its ATOM-seq technology available for research use later this year.
The team's Pro-Code system enabled simultaneous high-dimensional protein-level phenotyping of hundreds of genes with single-cell resolution.
The companies will work on applying barcoding technology to single-cell measurements of gene and protein expression and to immune cell profiling.
By using array-synthesized guide-donor oligonucleotide pairs, the team's gene editing technique allows accurate and detectable phenotyping in yeast cells.
The team plans to eventually implement the MSI test clinically to determine whether patients are eligible for immunotherapy.
The planned instrument will help provide spatial information on both protein and RNA in tumor samples and will be powered by nCounter technology.
Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.
Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.
The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.
In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.